Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial-Reference-Cited by-同舟云学术

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial

Published:2023-10 Issue:4 Volume:62 Page:2300262
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Molina-Molina Maria,Shull Jessica Germaine,Vicens-Zygmunt Vanesa^ORCID,Rivera-Ortega Pilar,Antoniou Katerina^ORCID,Bonella Francesco^ORCID,Renzoni Elisabetta,Russell Anne-Marie^ORCID,Maher Toby M.,Vancheri Ada,Bachs Anna,Avilés Victoria,Palma Josep,Bermudo Guadalupe,Suarez-Cuartin Guillermo^ORCID,Tebé Cristian,Rigo-Bonnin Raul,Montes-Worboys Ana,Wijsenbeek Marlies,Vancheri Carlo

Funder

F. Hoffmann La Roche

Instituto de Salud Carlos III

European Regional Development Fund

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference15 articles.

1. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

2. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

3. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

4. Idiopathic pulmonary fibrosis: current and future treatment;Glass;Clin Respir J,2022

5. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging roles of ferroptosis in pulmonary fibrosis: current perspectives, opportunities and challenges;Cell Death Discovery;2024-06-24

2. What has antifibrotic therapy changed for patients with idiopathic pulmonary fibrosis;Meditsinskiy sovet = Medical Council;2024-06-05

3. Targeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis;Cells;2024-04-30